Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D.GlobeNewsWire • 07/24/23
Editas (EDIT) Surges 15.5%: Is This an Indication of Further Gains?Zacks Investment Research • 06/14/23
Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL TrialGlobeNewsWire • 06/09/23
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta ThalassemiaGlobeNewsWire • 06/06/23
Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial OfficerGlobeNewsWire • 05/16/23
Editas Medicine, Inc. (EDIT) RBC Capital Markets Global Healthcare Conference 2023 TranscriptSeeking Alpha • 05/16/23
Editas Medicine, Inc. (EDIT) Bank of America Global Healthcare Conference Call TranscriptSeeking Alpha • 05/14/23
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 CongressGlobeNewsWire • 05/11/23
Nutcracker Therapeutics appoints Cynthia Collins, biopharma veteran and former Editas Medicine CEO, to board of directorsBusiness Wire • 05/09/23